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17-hydroxyprogesterone caproate does not prevent preterm birth in women with a twin
pregnancy and a prior singleton spontaneous preterm birth
Authors: Breanna Valcarcel, B.S., Andrew Ward, M.D., Huda Al-Kouatly, M.D., Victoria
Greenberg, M.D., Vincenzo Berghella M.D.

INTRODUCTION: Prior spontaneous preterm birth (sPTB) is a risk factor for recurrent sPTB.
Weekly 17-hydroxyprogesterone caproate (17P) is used to prevent sPTB in singletons, but there
is insufficient evidence on its benefit in twin pregnancies.
OBJECTIVE: We hypothesized that 17P weekly injections would reduce the likelihood of
sPTB in women carrying a twin pregnancy with a history of singleton sPTB.
METHODS: We performed a retrospective case control study of women with a twin gestation
and prior singleton sPTB between 2005 and 2016. The study group consisted of women with a
twin gestation that received weekly 17P starting at 16 to 20 weeks versus those who did not. The
primary outcome was twin sPTB <34 weeks. The secondary outcome was a composite neonatal
morbidity prior to hospital discharge.
RESULTS: Of 79 patients included, 27 women received weekly 17P and 52 did not. There were
no statistically significant differences in maternal demographics (except maternal age) or in the
rate of sPTB <34 weeks between cases and controls. There was no statistically significant
difference in the rate of sPTB <32 and <24 weeks, mean birth weight, or mode of delivery
between study and control groups. Composite neonatal morbidity occurred in 20 neonates (74%)
in the study group and in 41 control pregnancies (79%).

DISCUSSION: Weekly 17P injections do not appear to decrease the incidence of sPTB or
neonatal complications in twin pregnancies with a history of prior singleton sPTB. This study
will therefore guide future patient management on this common obstetric dilemma.

